Veracyte, Inc. (VCYT) Stock

Healthcare · Diagnostics & Research · Member of Other US Stocks

Veracyte, Inc. (VCYT) closed at USD 43.51 on 2026-10-14, a change of +22.2 % over the past year, with a market capitalization of USD 3.57B.

Veracyte, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Veracyte, Inc. key figures

Previous close

USD 43.51 (2026-10-14)

1-year change

+22.2 %

Market cap

USD 3.57B

Enterprise value

USD 3.12B

P/E ratio (trailing)

31.48

P/E ratio (forward)

22.82

EPS (trailing)

1.41

EPS (forward)

1.95

PEG ratio

n/a

Price to book

2.57

Revenue growth

15.5 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

7.05

Employees

755

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Veracyte, Inc.

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Veracyte, Inc. and compare it with other stocks.